

**PP32**

**FIRST 30 FOCAL ONE® PROSTATE FOCAL THERAPY: SHORT TERM EVALUATION**

S. Regusci, M. Martins-Favre, C.H. Rochat, G.A. De Boccard, I. Szalay-Quinodoz, S. Rohner

*SIPC Swiss International Prostate Center, Geneva, Switzerland*

**Introduction & Objectives:** To evaluate Prostate focal therapy by high-intensity focused ultrasound (Focal One® EDAP France) preliminary results in term of prostate cancer control and complications rate, we reviewed our first 30 cases in a retrospective way.

**Methods:** Between October 2014 and November 2015 we treated 30 patients with localized Prostate cancer. Inclusion criteria were maximum PSA 15ng/ml, Clinical stage T2, Maximum Gleason 3+4. We performed focal therapy by Focal One Device. True focal, zonal or hemiablation were adopted depending on the grade and extent of the tumor. Short term PSA, MRI and biopsies results and complications rate were evaluated.

Results: Mean age was 68 (53-74) years, median PSA was 9,1 (4,7-14,3) ng/, and the mean prostate volume was 43 (23-94cc). 15 patients harbored Gleason 3+3=6, and 15 Gleason 3+4=7. 16 patients underwent TURP or TUIP. All patients underwent contrast-enhanced ultrasound (SonoVue®). 12 immediate retreatments. In term of complications, one patient experienced severe incontinence for 3 months and 4 patients de novo erectile dysfunction. No fistula and urethral stricture were observed. PSA declined more than 50% of the initial value in 83,3% (25/30) patients. Biopsies performed between 8-12 months postoperatively were negatives in the lobe treated in 86,6% (26/30) patients.

**Conclusions:** Short term results in our small serie, show that Prostate focal therapy by Focal One is a safe procedure with promising oncological results.